Neurocrine Biosciences, Inc. (NBIX) Stock Still Strong Despite Competition
Wells Fargo raised the price target for the Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock from “an Equal weight” to “an Overweight”. The rating was released on Apr-25-24, according to finviz. The research report from Deutsche Bank has initiated the stock to Buy, with a price target set at $136. The stock was resumed by Cantor Fitzgerald, […]
Neurocrine Biosciences, Inc. (NBIX) Stock: Pessimism is a stepping stone to opportunity
Citigroup raised the price target for the Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock to “a Neutral”. The rating was released on December 13, 2023, according to finviz. The research report from Cantor Fitzgerald has resumed the stock to Overweight, with a price target set at $140. The stock was reiterated by Mizuho, who disclosed in a […]
Neurocrine Biosciences, Inc. (NBIX) Stock deserves your attention
Citigroup raised the price target for the Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock to “a Neutral”. The rating was released on December 13, 2023, according to finviz. The research report from Cantor Fitzgerald has resumed the stock to Overweight, with a price target set at $140. The stock was reiterated by Mizuho, who disclosed in a […]
Why Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock rose 23.08% in Last Six Months?
Citigroup raised the price target for the Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock to “a Neutral”. The rating was released on December 13, 2023, according to finviz. The research report from Cantor Fitzgerald has resumed the stock to Overweight, with a price target set at $140. The stock was reiterated by Mizuho, who disclosed in a […]
Why Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Jumped 1.32% in Last Month?
Citigroup raised the price target for the Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock to “a Neutral”. The rating was released on December 13, 2023, according to finviz. The research report from Cantor Fitzgerald has resumed the stock to Overweight, with a price target set at $140. The stock was reiterated by Mizuho, who disclosed in a […]
Why Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock up 3.29% in Last Week?
Citigroup raised the price target for the Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock to “a Neutral”. The rating was released on December 13, 2023, according to finviz. The research report from Cantor Fitzgerald has resumed the stock to Overweight, with a price target set at $140. The stock was reiterated by Mizuho, who disclosed in a […]
